Mari Ariyasu
-
- Antibiotic Use and Resistance 7
- Molecular Medicine top 0.2%
- Antibiotic Resistance in Bacteria 15
- Pharmacology top 1%
- Antibiotics Pharmacokinetics and Efficacy 17
- Endocrinology top 2%
-
- SARS-CoV-2 and COVID-19 Research 7
-
- Urinary Tract Infections Management 4
- Pneumonia and Respiratory Infections 4
-
- Bacterial Identification and Susceptibility Testing 3
-
- Animal Virus Infections Studies 3
- Co-authors
- Tsutae Den NagataRoger EcholsSimon PortsmouthYuko MatsunagaRichard G. WunderinkJuan Camilo Arjona FerreiraMitsuaki MachidaDavid van Veenhuyzen
- Journals
- Open Forum Infectious Diseases (10 papers)Vaccine (4 papers)The Lancet Infectious Diseases (3 papers)
- Partner nations
- JapanUnited StatesUnited Kingdom
In The Last Decade
Mari Ariyasu
25 papers receiving 1.5k citations
Hit Papers
Peers
Comparison fields: 5 of 79
- Applied Microbiology and Biotechnology 561
- Molecular Medicine 1.2k
- Pharmacology 873
- Endocrinology 183
- Critical Care and Intensive Care Medicine 108
Countries citing papers authored by Mari Ariyasu
This map shows the geographic impact of Mari Ariyasu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mari Ariyasu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mari Ariyasu more than expected).
Fields of papers citing papers by Mari Ariyasu
This network shows the impact of papers produced by Mari Ariyasu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mari Ariyasu. The network helps show where Mari Ariyasu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mari Ariyasu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 4 | |
| 4 | 2024 | 2 | |
| 5 | 2023 | 1 | |
| 6 | 2022 | 12 | |
| 7 | 2022 | 11 | |
| 8 | 2022 | 2 | |
| 9 | 2020 | 2 | |
| 10 | Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trialbreakdown → | 2020 | 319 |
| 11 | 2020 | 5 | |
| 12 | 2020 | 3 | |
| 13 | Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trialbreakdown → | 2020 | 540 |
| 14 | 2020 | 1 | |
| 15 | 2019 | 27 | |
| 16 | 2019 | 25 | |
| 17 | 2019 | 13 | |
| 18 | Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trialbreakdown → | 2018 | 305 |
| 19 | 2017 | 24 | |
| 20 | 2017 | 139 |
About Mari Ariyasu
Mari Ariyasu is a scholar working on Applied Microbiology and Biotechnology, Molecular Medicine and Pharmacology, having authored 26 papers that have together received 1.5k indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (17 papers), Antibiotic Resistance in Bacteria (15 papers), SARS-CoV-2 and COVID-19 Research (7 papers), Antibiotic Use and Resistance (7 papers), Urinary Tract Infections Management (4 papers), Pneumonia and Respiratory Infections (4 papers), Bacterial Identification and Susceptibility Testing (3 papers) and Animal Virus Infections Studies (3 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (561 citations), Molecular Medicine (1.2k citations) and Pharmacology (873 citations). Mari Ariyasu has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Tsutae Den Nagata, Roger Echols, Simon Portsmouth, Yuko Matsunaga, Richard G. Wunderink, Juan Camilo Arjona Ferreira, Mitsuaki Machida, David van Veenhuyzen, Matteo Bassetti and Kiichiro Toyoizumi. Their work appears in journals such as Open Forum Infectious Diseases, Vaccine, The Lancet Infectious Diseases, Clinical Infectious Diseases and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.